blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2349210

EP2349210 - PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.01.2016
Database last updated on 09.09.2024
Most recent event   Tooltip22.06.2018Lapse of the patent in a contracting state
New state(s): MK		published on 25.07.2018  [2018/30]
Applicant(s)For all designated states
Marina Biotech, Inc.
3830 Monte Villa Parkway
Bothell WA 98021-7266 / US
[2011/31]
Inventor(s)01 / POLISKY, Barry, A.
449 Mountain View Road
Boulder CO 80302 / US
02 / ADAMI, Roger, C.
18719 36th Dr.SE
Bothell WA 98012 / US
03 / TEMPLIN, Michael, V.
19112 30th Drive SE
Bothell WA 98012 / US
04 / HARVIE, Pierrot
17725 Hall Road 105
Bothell WA 98011 / US
05 / JOHNS, Rachel, E.
2503 Ne 150th Street
Shoreline WA 98155 / US
06 / GIYANANI, Jaya, S.
16275 NE 85th Street 308
Redmond WA 98052 / US
07 / HOUSTON, Michael, E.
15 Horseshoe Drive
Acton MA 01720 / US
 [2011/31]
Representative(s)Roques, Sarah Elizabeth
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
[2015/12]
Former [2011/31]Roques, Sarah Elizabeth
J.A. Kemp & Co. 14 South Square Gray's Inn
London WC1R 5JJ / GB
Application number, filing date09744527.416.10.2009
[2011/31]
WO2009US60930
Priority number, dateUS20080106062P16.10.2008         Original published format: US 106062 P
US20090167379P07.04.2009         Original published format: US 167379 P
[2011/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010045512
Date:22.04.2010
Language:EN
[2010/16]
Type: A2 Application without search report 
No.:EP2349210
Date:03.08.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 22.04.2010 takes the place of the publication of the European patent application.
[2011/31]
Type: B1 Patent specification 
No.:EP2349210
Date:18.03.2015
Language:EN
[2015/12]
Search report(s)International search report - published on:EP27.01.2011
ClassificationIPC:A61K9/127, A61K48/00, C12N15/11, C12N15/88
[2011/31]
CPC:
A61K9/1271 (EP,US); A61K9/127 (KR,US); A61K48/00 (KR);
A61K9/1277 (US); A61P1/16 (EP); A61P13/10 (EP);
A61P19/00 (EP); A61P19/02 (EP); A61P19/08 (EP);
A61P25/00 (EP); A61P29/00 (EP); A61P3/00 (EP);
A61P3/06 (EP); A61P31/12 (EP); A61P35/00 (EP);
A61P43/00 (EP); A61P9/00 (EP); C12N15/11 (KR);
C12N15/111 (EP,US); C12N15/113 (US); C12N15/88 (EP,KR,US);
C12N2310/14 (EP,US); C12N2320/32 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/31]
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR LIPOSOMALEN UND EFFIZIENTEN ZUFÜHRUNG VON GENE-SILENCING-THERAPEUTIKA[2011/31]
English:PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS[2011/31]
French:PROCÉDÉS ET COMPOSITIONS POUR UNE ADMINISTRATION LIPOSOMALE ET EFFICACE DE PRODUITS THÉRAPEUTIQUES DE SILENÇAGE DE GÈNE[2011/31]
Entry into regional phase12.05.2011National basic fee paid 
12.05.2011Designation fee(s) paid 
12.05.2011Examination fee paid 
Examination procedure12.05.2011Examination requested  [2011/31]
20.12.2011Amendment by applicant (claims and/or description)
22.03.2012Despatch of a communication from the examining division (Time limit: M06)
18.09.2012Reply to a communication from the examining division
29.11.2013Despatch of a communication from the examining division (Time limit: M06)
30.05.2014Reply to a communication from the examining division
09.10.2014Communication of intention to grant the patent
09.02.2015Fee for grant paid
09.02.2015Fee for publishing/printing paid
09.02.2015Receipt of the translation of the claim(s)
Divisional application(s)EP15153333.8  / EP2902013
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  22.03.2012
Opposition(s)21.12.2015No opposition filed within time limit [2016/08]
Fees paidRenewal fee
11.10.2011Renewal fee patent year 03
11.10.2012Renewal fee patent year 04
25.03.2014Renewal fee patent year 05
14.10.2014Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.10.201305   M06   Fee paid on   25.03.2014
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.10.2009
AT18.03.2015
BE18.03.2015
BG18.03.2015
CY18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
MC18.03.2015
MK18.03.2015
MT18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
SM18.03.2015
TR18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
IE16.10.2015
LU16.10.2015
CH31.10.2015
LI31.10.2015
[2018/30]
Former [2017/38]HU16.10.2009
AT18.03.2015
BE18.03.2015
BG18.03.2015
CY18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
MC18.03.2015
MT18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
SM18.03.2015
TR18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
IE16.10.2015
LU16.10.2015
CH31.10.2015
LI31.10.2015
Former [2016/45]AT18.03.2015
BE18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
MC18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
IE16.10.2015
LU16.10.2015
CH31.10.2015
LI31.10.2015
Former [2016/37]AT18.03.2015
BE18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
MC18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
LU16.10.2015
CH31.10.2015
LI31.10.2015
Former [2016/34]AT18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
MC18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
LU16.10.2015
CH31.10.2015
LI31.10.2015
Former [2016/28]AT18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
MC18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
LU16.10.2015
Former [2016/26]AT18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
LU16.10.2015
Former [2016/12]AT18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SI18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
Former [2016/07]AT18.03.2015
CZ18.03.2015
DK18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
Former [2016/03]AT18.03.2015
CZ18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
IT18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
Former [2015/51]AT18.03.2015
CZ18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
Former [2015/50]CZ18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
PL18.03.2015
RO18.03.2015
SE18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
IS18.07.2015
PT20.07.2015
Former [2015/49]CZ18.03.2015
EE18.03.2015
ES18.03.2015
FI18.03.2015
HR18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
RO18.03.2015
SE18.03.2015
SK18.03.2015
NO18.06.2015
GR19.06.2015
PT20.07.2015
Former [2015/41]FI18.03.2015
HR18.03.2015
LT18.03.2015
LV18.03.2015
NL18.03.2015
SE18.03.2015
NO18.06.2015
GR19.06.2015
Former [2015/39]FI18.03.2015
HR18.03.2015
LT18.03.2015
LV18.03.2015
SE18.03.2015
NO18.06.2015
GR19.06.2015
Former [2015/37]FI18.03.2015
HR18.03.2015
LT18.03.2015
SE18.03.2015
NO18.06.2015
GR19.06.2015
Former [2015/36]FI18.03.2015
HR18.03.2015
LT18.03.2015
SE18.03.2015
NO18.06.2015
Former [2015/35]LT18.03.2015
NO18.06.2015
Cited inInternational search[AP]WO2008137758  (NASTECH PHARM CO [US], et al) [AP] 1-34 * the whole document * * page 90, line 14 *;
 [AP]WO2009046220  (MDRNA INC [US], et al) [AP] 1-34;
 [Y]  - GABIZON AA ET AL., "Pros and cons of the liposome platform in cancer drug targeting", JOURNAL OF LIPOSOME RESEARCH, (2006), vol. 16, no. 3, ISSN 0898-2104, pages 175 - 183, XP002591241 [Y] 1-34 * the whole document *

DOI:   http://dx.doi.org/10.1080/08982100600848769
 [Y]  - MAINARDES R M ET AL, "Liposomes and micro/nanoparticles as colloidal carriers for nasal drug delivery", CURRENT DRUG DELIVERY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, (20060101), vol. 3, no. 3, doi:10.2174/156720106777731019, ISSN 1567-2018, pages 275 - 285, XP009095996 [Y] 1-34 * the whole document *

DOI:   http://dx.doi.org/10.2174/156720106777731019
 [Y]  - SHARMA A ET AL, "LIPOSOMES IN DRUG DELIVERY: PROGRESS AND LIMITATIONS", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (19970101), vol. 154, no. 2, doi:10.1016/S0378-5173(97)00135-X, ISSN 0378-5173, pages 123 - 140, XP008047948 [Y] 1-34 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0378-5173(97)00135-X
 [Y]  - MINGHUI FAN ET AL, "Preparation of salidroside nano-liposomes by ethanol injection method and in vitro release study", EUROPEAN FOOD RESEARCH AND TECHNOLOGY, ZEITSCHRIFT FÜR LEBENSMITTELUNTERSUCHUNG UND -FORSCHUNG A, SPRINGER, BERLIN, DE, (20070725), vol. 227, no. 1, ISSN 1438-2385, pages 167 - 174, XP019621668 [Y] 1-34 * the whole document * * page 168, column 2, paragraph 2 *
 [Y]  - MAITANI Y ET AL, "MODIFIED ETHANOL INJECTION METHOD FOR LIPOSOMES CONTAINING beta-SITOSTEROL beta-D-GLUCOSIDE.", JOURNAL OF LIPOSOME RESEARCH, (2001), vol. 11, no. 1, ISSN 1532-2394, pages 115 - 125, XP002591242 [Y] 1-34 * the whole document * * page 117; figures 2,3; table 1 *
 [Y]  - PONS M ET AL, "Liposomes obtained by the ethanol injection method", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 95, no. 1-3, doi:10.1016/0378-5173(93)90389-W, ISSN 0378-5173, (19930630), pages 51 - 56, (19930630), XP023831858 [Y] 1-34 * the whole document * * page 52 *

DOI:   http://dx.doi.org/10.1016/0378-5173(93)90389-W
 [Y]  - SKALKO NATASA ET AL, "Liposomes with nifedipine and nifedipine-cyclodextrin complex: Calorimetrical and plasma stability comparison", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, (1996), vol. 4, no. 6, ISSN 0928-0987, pages 359 - 366, XP002591243 [Y] 1-34 * the whole document * * paragraph [02.3] *
 [A]  - FREDERIKSEN LENE ET AL, "Preparation of liposomes encapsulating water-soluble compounds using supercritical carbon dioxide", JOURNAL OF PHARMACEUTICAL SCIENCES, (1997), vol. 86, no. 8, ISSN 0022-3549, pages 921 - 928, XP002591244 [A] 1-34
 [A]  - MAITANI ET AL, "Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (20070817), vol. 342, no. 1-2, doi:10.1016/J.IJPHARM.2007.04.035, ISSN 0378-5173, pages 33 - 39, XP022206304 [A] 1-34

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2007.04.035
Examination   - NGUYEN T ET AL, "RNAi therapeutics: An update on delivery", CURRENT OPINION IN MOLECULAR THERAPEUTICS 200804 GB, (200804), vol. 10, no. 2, ISSN 1464-8431, pages 158 - 167
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.